- Home
- WK vs AKRO Comparison
WK vs AKRO Comparison
Compare WK & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WK
- AKRO
- Stock Information
- Founded
- WK 2008
- AKRO 2017
- Country
- WK United States
- AKRO United States
- Employees
- WK N/A
- AKRO N/A
- Industry
- WK Computer Software: Prepackaged Software
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- WK Technology
- AKRO Health Care
- Exchange
- WK Nasdaq
- AKRO Nasdaq
- Market Cap
- WK 4.5B
- AKRO 3.7B
- IPO Year
- WK 2014
- AKRO 2019
- Fundamental
- Price
- WK $88.52
- AKRO $53.79
- Analyst Decision
- WK Strong Buy
- AKRO Buy
- Analyst Count
- WK 10
- AKRO 10
- Target Price
- WK $102.20
- AKRO $73.56
- AVG Volume (30 Days)
- WK 794.1K
- AKRO 4.0M
- Earning Date
- WK 11-05-2025
- AKRO 11-07-2025
- Dividend Yield
- WK N/A
- AKRO N/A
- EPS Growth
- WK N/A
- AKRO N/A
- EPS
- WK N/A
- AKRO N/A
- Revenue
- WK $806,977,000.00
- AKRO N/A
- Revenue This Year
- WK $21.54
- AKRO N/A
- Revenue Next Year
- WK $15.73
- AKRO N/A
- P/E Ratio
- WK N/A
- AKRO N/A
- Revenue Growth
- WK 19.02
- AKRO N/A
- 52 Week Low
- WK $60.50
- AKRO $21.34
- 52 Week High
- WK $116.83
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- WK 56.57
- AKRO 68.53
- Support Level
- WK $86.16
- AKRO $53.40
- Resistance Level
- WK $91.69
- AKRO $53.93
- Average True Range (ATR)
- WK 2.63
- AKRO 0.26
- MACD
- WK -0.18
- AKRO 0.01
- Stochastic Oscillator
- WK 53.92
- AKRO 34.51
About WK Workiva Inc.
Workiva Inc is a cloud-native platform that simplifies the complexities of reporting and compliance. Workiva platform empowers customers by connecting and transforming data from hundreds of enterprise resource planning (ERP), human capital management (HCM), and customer relationship management (CRM) systems, as well as other third-party cloud and on-premise applications. Customers use the platform to create, review and publish data-linked documents and reports with greater control, consistency, accuracy, and productivity and it is also used for SEC Filings. Company's Geographical region consist of USA, Netherland, UK, and Others. Majority of revenue is from USA.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.